Case series of reports of pruritus and sipuleucel-T submitted to the Food and Drug Administration Adverse Event Reporting System

Sipuleucel-T, an autologous active cellular immunotherapy, is indicated for the treatment of asymptomatic or minimally symptomatic castration-resistant prostate cancer. The U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) received a report of pruritus without rash following t...

Descripción completa

Detalles Bibliográficos
Autores principales: Dores, Graça M., Perez-Vilar, Silvia, Niu, Manette T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923907/
https://www.ncbi.nlm.nih.gov/pubmed/31890238
http://dx.doi.org/10.1186/s40780-019-0156-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923907/
https://www.ncbi.nlm.nih.gov/pubmed/31890238
http://dx.doi.org/10.1186/s40780-019-0156-0

Ejemplares similares